Lancastotug Biosimilar – Anti-VSTM3 mAb – Research Grade

Lancastotug Biosimilar – Anti-VSTM3 mAb – Research Grade: A Promising Antibody for Therapeutic Targeting Lancastotug Biosimilar – Anti-VSTM3 mAb (monoclonal antibody) is a novel therapeutic agent that has shown promising results in preclinical studies for the treatment of various diseases. This biosimilar is a highly specific antibody that targets the VSTM3 protein, making it a potential therapeutic option for a wide range of conditions.

Structure of Lancastotug Biosimilar – Anti-VSTM3 mAb

The Lancastotug Biosimilar – Anti-VSTM3 mAb is a recombinant humanized monoclonal antibody, meaning that it is produced in the laboratory using genetic engineering techniques. It is a Y-shaped protein with two identical arms, each containing a heavy chain and a light chain. The heavy and light chains are connected by disulfide bonds and each arm has a variable region that recognizes and binds to the VSTM3 protein.

The constant region of the antibody is responsible for triggering immune responses and determining the antibody’s class. Lancastotug Biosimilar – Anti-VSTM3 mAb belongs to the IgG1 class, which is the most abundant antibody in the human body and is known for its long half-life and ability to activate immune cells.

Activity of Lancastotug Biosimilar – Anti-VSTM3 mAb

The primary function of Lancastotug Biosimilar – Anti-VSTM3 mAb is to bind to the VSTM3 protein and block its activity. VSTM3 is a cell surface protein that is found in high levels on certain types of cancer cells, as well as on immune cells involved in inflammatory responses. By targeting VSTM3, Lancastotug Biosimilar – Anti-VSTM3 mAb can inhibit the growth and survival of cancer cells and modulate immune responses to reduce inflammation.

In addition to its direct effects on VSTM3, Lancastotug Biosimilar – Anti-VSTM3 mAb also has secondary effects on other cellular pathways. For example, it can activate immune cells such as natural killer cells and macrophages, which can further enhance its anti-tumor and anti-inflammatory effects.

Application of Lancastotug Biosimilar – Anti-VSTM3 mAb

Lancastotug Biosimilar – Anti-VSTM3 mAb has shown promising results in preclinical studies for the treatment of various diseases, including cancer and inflammatory disorders. In cancer, it has been shown to inhibit the growth and spread of tumors in animal models, and it is currently being evaluated in clinical trials for several types of cancer, including lung, breast, and ovarian cancer.

In addition to its potential as a cancer treatment, Lancastotug Biosimilar – Anti-VSTM3 mAb also has potential applications in the treatment of inflammatory disorders such as rheumatoid arthritis and inflammatory bowel disease. By targeting VSTM3, it can modulate immune responses and reduce inflammation, which is a key factor in these diseases.

Conclusion

Lancastotug Biosimilar – Anti-VSTM3 mAb is a promising antibody for therapeutic targeting due to its highly specific binding to the VSTM3 protein and its ability to modulate immune responses. Its potential applications in cancer and inflammatory disorders make it a valuable addition to the arsenal of biologic therapies. Further clinical studies will determine its efficacy and safety in treating these diseases, but early results are promising and warrant further investigation.

Keywords: Lancastotug Biosimilar, Anti-VSTM3 mAb, monoclonal antibody, therapeutic target, cancer, inflammatory disorders, immune responses.

ProteoGenix catalogue number PX-TA2124. For research use only.

Target: Lancastotug Biosimilar – Anti-VSTM3 mAb – Research Grade; Clonality: Monoclonal Antibody; Expression system: XtenCHO; Purity: >95% by SDS-PAGE.; Buffer: 0.01M PBS, pH 7.4.; Applications: ELISA, WB.

Available configurations: 50ug, 100ug, 1mg.

Download the manufacturer datasheet